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Abstract
Background: The early to intermediate stages of the majority of colorectal tumours are thought to be
driven by aberrations in the Wnt (APC, CTNNB1) and Ras (K-ras) pathways. A smaller proportion of
cancers shows mismatch repair deficiency. The aim of this study was to analyse the co-occurrence of these
genetic alterations in relation to tumour and patient characteristics.
Methods: In a group of 656 unselected sporadic colorectal cancer patients, aberrations in the APC, K-ras,
CTNNB1 genes, and expression of hMLH1 were investigated. Additionally, tumours were divided in groups
based on molecular features and compared with respect to patient's age at diagnosis, sex, family history
of colorectal cancer, tumour sub-localisation, Dukes' stage and differentiation.
Results: Mutations at the phosphorylation sites (codons 31, 33, 37, and 45) in the CTNNB1 gene were
observed in tumours from only 5/464 patients. Tumours with truncating APC mutations and activating K-
ras mutations in codons 12 and 13 occurred at similar frequencies (37% (245/656) and 36% (235/656),
respectively). Seventeen percent of tumours harboured both an APC and a K-ras mutation (109/656). Nine
percent of all tumours (58/656) lacked hMLH1 expression. Patients harbouring a tumour with absent
hMLH1 expression were older, more often women, more often had proximal colon tumours that showed
poorer differentiation when compared to patients harbouring tumours with an APC and/or K-ras mutation.
Conclusion: CTNNB1 mutations seem to be of minor importance in sporadic colorectal cancer. The main
differences in tumour and patient characteristics are found between groups of patients based on mismatch
repair deficiency.
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Carcinogenesis is a multi-step process that involves the
accumulation of numerous genetic and epigenetic
changes in cells [1]. These genetic aberrations affect a lim-
ited number of identified pathways that are involved in
(colorectal) carcinogenesis [2]. A genetic model for spo-
radic colorectal cancer has been proposed, which
describes the sequential accumulation of specific genetic
alterations in various pathways, involving tumour sup-
pressor genes (e.g. APC, SMAD4, TP53) and oncogenes
(e.g. CTNNB1, K-ras) [3,4]. Important molecular path-
ways that upon activation affect the early and intermedi-
ate stages of colorectal carcinogenesis are the Wnt and Ras
signalling pathways, whereas TP53 inactivation is consid-
ered a late event.
Activation of the Wnt pathway plays a central role in the
aetiology of most colorectal cancers and is often the result
of mutations in the N-terminal domain of the APC gene,
that lead to partial or complete loss of this region and
thereby to loss of the β-catenin regulating function [5,6].
Conversely, in tumours lacking these APC mutations [7],
activating missense mutations at one of the phosphoryla-
tion sites at codons 31, 33, 37 and 45 of exon 3 of the
CTNNB1 gene (encoding the β-catenin protein) can
render it stable as it can no longer be tagged for cellular
degradation. Activation of the Ras pathway in cancer is
marked by the loss of the intrinsic GTPase activity of the
Ras protein, which can be ascribed to missense mutations
in codons 12 and 13 of exon 1, which are responsible for
90% activating mutations in the of the K-ras gene [8].
According to the paradigm for colorectal cancer develop-
ment, mutations in the APC and K-ras are thought to con-
tribute to the early developmental stages of colorectal
cancer [3]. However, a recent study based on the analysis
of APC, K-ras and TP53 genes concluded that simultane-
ous occurrence of all three genetic alterations is rare and
that multiple genetic pathways may be relevant to color-
ectal cancer [9].
Genetic instability is seen in most types of cancer [10].
Two distinct types of genetic instability appear to occur in
colorectal cancer [11]: chromosomal and microsatellite
instability. Chromosomal instability results in gains or
losses of entire chromosomes or parts of them, and gives
rise to aneuploid tumours and occurs in the majority of
cancers. A smaller proportion of colorectal cancers dis-
plays microsatellite instability, represented by diploid
cells acquiring high mutation rates, and was found to be
associated with defective mismatch repair [12]. These
tumours are less likely to harbour mutations in genes
associated with chromosomally instable and generally
aneuploid tumours, such as APC, K-ras and TP53 [13-21],
suggesting that these tumours form a distinct group.
Moreover, microsatellite instable tumours are found pre-
dominantly in the proximal colon [22,23], are more likely
to occur in patients with a positive family history of color-
ectal cancer [22,23], are often less differentiated than mic-
rosatellite stable tumours [22], and occur more frequently
in women [24] and at older age [25]. Moreover, in
tumours displaying microsatellite instability, mutations
the CTNNB1 gene were more frequent [26].
Considering the aforementioned issues, there is a need for
studies addressing the heterogeneity of affected genes
involved in early to intermediate colorectal cancer devel-
opment in large groups of patients. We have previously
studied the occurrence of APC and K-ras mutations sepa-
rately [27,28]. In the current study, in addition to investi-
gating mutations in the APC, CTNNB1 and K-ras genes as
well as mismatch repair deficiency by means of hMLH1
expression, and combinations of these aberrations, their
relation with various tumour and patient characteristics
were studied in a large, unselected group of incident color-
ectal cancer patients.
Methods
Study population
The prospective Netherlands Cohort Study on diet and
cancer was initiated in September 1986. The study design
has been described in detail elsewhere [29]. The study
population originated from 204 municipal population
registries throughout the Netherlands, and included a
total of 58,279 men and 62,573 women between the ages
of 55 and 69 years at baseline.
Incident cancer cases are identified by monitoring of the
entire cohort for cancer occurrence through annual record
linkage to the Netherlands Cancer Registry, i.e. nine
regional cancer registries throughout the Netherlands,
and to PALGA, a nationwide network and registry of
histo- and cytopathology [30]. Together, the NCR and
PALGA provide a near 100% coverage of the municipali-
ties included in the NLCS. The first 2.3 years of follow up
were excluded because of possible pre-clinical disease
affecting exposure status and because of incomplete
nationwide coverage of PALGA in some of the municipal-
ities included in the NLCS in that period. From 1989 until
1994, 929 incident cases with histologically confirmed
colorectal cancer were identified within the cohort, of
whom 819 could also be linked to a PALGA report of the
lesion.
The PALGA reports were used to identify and locate
tumour tissue from eligible colorectal cancer patients in
Dutch pathology laboratories. Colon and rectal cancer
were classified according to site as follows, colon: cecum
through sigmoid colon (ICD-O codes 153.0, 153.1,Page 2 of 11
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(ICD-O code 154.0), and rectum (ICD-O code 154.1).
Tissue samples
Tumour material of colorectal cancer patients was col-
lected after approval by the Ethical Review Board of Maas-
tricht University, PALGA and the NCR. Tissue samples
from 819 colorectal cancer patients were localized in 54
pathology laboratories throughout the Netherlands.
Forty-four (5%) tumour tissue samples could not be
retrieved from the pathology archives. Of 775 available
tissue samples, 737 (95%) contained sufficient tumour
material for molecular analyses. Tissue sections were cut
from each sample, which were used for DNA isolation and
immunohistochemical analysis.
DNA isolation
DNA isolation was described in detail elsewhere [27].
Briefly, a 4 µm section, cut from each paraffin-embedded
tumour tissue block, was stained with haematoxylin and
eosin (HE) for histopathological examination by a
pathologist. Five 20 µm sections of tumour tissue were cut
from each sample for DNA isolation. Tumour tissue was
separated from normal colon epithelium using the HE
section as a reference. Genomic DNA was extracted from
macrodissected tumour tissue using proteinase K (Qiagen,
St. Louis, MO, USA) and the Puregene DNA isolation kit
(Gentra Systems, Minneapolis, MN, USA). DNA concen-
tration and purity was measured at 260 and 280 nm.
K-ras mutation analysis
Mutation analysis of the exon 1 fragment of the K-ras
oncogene, spanning codons 8–29, was performed on
archival colorectal adenocarcinoma specimens of 737
patients, using nested PCR, followed by direct sequencing
of purified fragments [27]. The detection limit was 5%
mutated DNA and duplicate experiments revealed a good
reproducibility (88%) [27].
APC mutation analysis
The majority of somatic mutations in the APC gene are
found within the mutation cluster region (codons 1286–
1520). Mutation analysis of the mutation cluster region
was performed on adenocarcinoma DNA using nested
PCR for amplification of the mutation cluster region as
four overlapping DNA fragments followed by direct
sequencing of purified fragments, as previously described
[28]. An alternative nested PCR strategy was performed
when nested PCR failed for any of the fragments, using
different primers. The detection limit was 5% mutated
DNA and duplicate experiments revealed good reproduc-
ibility (85%)[28]. From 72 of the 737 patients with suffi-
cient DNA yield, one or more fragments of the mutation
cluster region could not be amplified and these patients
were not included in this study.
CTNNB1 mutation analysis
All 464 samples without a truncating APC mutation (n =
411) and all samples with absent hMLH1 expression (n =
58) were analysed for mutations in the phosphorylation
sites at codons 33, 37, 41 and 45 in exon 3 of the CTNNB1
gene. This selection was made, since most mutations are
expected in these samples. Tumours lacking truncating
APC mutations may harbour CTNNB1 mutations [7], and
microsatellite instable tumours are also expected to more
frequently have mutations in CTNNB1 [26].
Amplification of exon 3 of the CTNNB1 gene entailed a
semi-nested PCR strategy, which covered codons 33, 37,
41 and 45. Flank PCR was performed to generate a 308 bp
fragment (primers, forward: 5'-CCAATCTACTAAT-
GCTAATACTG-3', reverse: 5'-GCATTCTGACTTTCAG-
TAAGGC-3') that was used in a 1:100 dilution for
amplification of the final PCR product (primers, forward:
5'-CCAATCTACTAATGCTAATACTG-3', reverse: 5'-CTTC-
CTCAGGATTGCCTTTACC-3'). In each PCR, one round of
35 cycles was performed.
The semi-nested PCR products from samples without a
truncating APC mutation were screened for mutations
using denaturing high-pressure liquid chromatography
(dHPLC) on a WAVE 3500 HT system (Transgenomic Inc.,
UK). WAVE analysis was optimised and validated using
specific mutations in cell line DNA, i.e. HCT116 (codon
45: 3 bp deletion) and SW48 (codon 33: C→A) as well as
DNA derived from desmoid tumours from patients
(codon 41: A→G and codon 45: C→T) as positive con-
trols. All of these mutations were repeatedly confirmed by
sequencing. WAVE analysis was carried out at two differ-
ent temperatures (57.7 en 60°C). Samples showing an
aberrant elution profile were re-amplified and re-
screened. When an aberrant elution profile was con-
firmed, direct sequencing was performed. All samples
without hMLH1 expression were analysed by direct
sequencing without screening. The sequence profile was
analysed on an ALFexpress II DNA analysis system using
ALFwin software (Amersham Biosciences, Roosendaal,
the Netherlands).
hMLH1 expression
Formalin-fixed, paraffin-embedded tissue sections cut at 4
µm, which included tumour tissue with normal adjacent
mucosa, were used for immunohistochemistry. Endog-
enous peroxidase activity was blocked by 3% H2O2. Slides
were submitted to microwave antigen retrieval in 1 mM
EDTA buffer (pH 8.0) and incubated with 10% normal
horse serum for ten min at room temperature. Then, sec-
tions were incubated overnight at 4°C with mouse mon-
oclonal antibodies against hMLH1 protein (clone G168-
15, PharMingen, San Diego, CA) at a 1:100 dilution. Anti-
body binding was detected by incubating the sections atPage 3 of 11
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Envision System (DAKO, Carpinteris, CA), using DAB as
a chromogen. Sections were counterstained with diluted
haematoxylin.
Lesions were considered to lack hMLH1 protein expres-
sion when unequivocal absence of nuclear staining of the
tumour epithelial cells was observed. Nuclear staining of
normal epithelial and stromal cells or lymphocytes served
as an internal positive control. Staining was scored inde-
pendently by at least two observers and in case of discord-
ant results discussed with a pathologist until consensus
was reached. hMLH1 expression could be determined in
724 of 737 patients.
BAT-26
Analysis of the BAT-26 mononucleotide repeat was per-
formed in a random sample of tumour specimens from
114 patients, and a series of 48 of 58 tumours that lacked
hMLH1 expression, to assess the concordance between
the microsatellite instability marker BAT-26 and hMLH1
expression. The primer sequences and PCR conditions for
the BAT-26 mononucleotide repeat were used as
described previously [31].
Statistical analysis
In the statistical analysis, data from 656 patients for
whom information on APC and K-ras mutation status as
well as hMLH1 expression was complete were included.
The χ2 test and Cramérs V test were used to estimate the
association of the co-occurrence of K-ras and APC gene
mutations. Characteristics of patients (age at diagnosis,
sex, family history of colorectal cancer) and tumours
(tumour sub-localisation, Dukes' stage and tumour differ-
entiation) were compared between patients with and
without an activating K-ras or a truncating APC mutation
as well as patients harbouring tumours with and without
hMLH1 expression, using Students T-test (age at diagno-
sis) and χ2 tests (sex, family history of colorectal cancer,
tumour sub-localisation, Dukes' stage and differentia-
tion). Additionally, patient and tumour characteristics of
tumours with an activating K-ras and/or a truncating APC
mutation were compared to tumours lacking hMLH1
expression. All P-values are reported for a two-sided test;
P-values of less than 0.05 were considered to be statisti-
cally significant.
Results
Tumours from 464 of 656 patients, which did not har-
bour a truncating APC mutation or lacked hMLH1 expres-
sion, were analysed for mutations in exon 3 of the
CTNNB1 gene. Table 1 describes the tumour and patient
characteristics of seven colorectal tumours that harboured
a mutation in CTNNB1 exon 3. In five colorectal cancers,
a CTNNB1 mutation that would lead to loss of one of the
Ser/Thr phosphorylation sites and subsequent stabilisa-
tion of the protein, occurred at codons 37 and 45, all were
C→T transitions, leading to Ser→Phe amino acid changes
and occurred in the proximal colon. All bar one also had
an activating mutation in the K-ras gene. Three of these
five tumours showed hMLH1 deficiency. Two colorectal
cancer patients harboured a mutation in the CTNNB1
gene, that did not occur at the Ser/Thr phosphorylation
sites, but would result in an amino acid alteration at
codons 22 and 29, the effects of which are unknown.
Table 1: Description of patient, tumour and molecular characteristics of colorectal cancers harbouring a CTNNB1 mutation.
Patienta Sex Age at 
diagnosis 
(yr)
Sub-
localisation
Dukes' 
stage
Tumour 
differentiation
Codon Mutation Amino 
acid 
change
hMLH1 
expressionb
Truncating 
APC 
mutationb
Activating 
K-ras 
mutation
1 M 65 Proximal 
colon
B Moderate 37 C→T Ser→Phe Present No Yes
2 M 67 Proximal 
colon
A Moderate 45 C→T Ser→Phe Absent No Yes
3 M 69 Proximal 
colon
B Good 45 C→T Ser→Phe Absent No No
4 M 61 Proximal 
colon
C Moderate 45 C→T Ser→Phe Present No Yes
5 F 69 Proximal 
colon
A Undifferentiated 45 C→T Ser→Phe Absent No Yes
6c M 69 Distal 
colon
B Moderate 22 G→A Val→Ile Present No Yes
7c F 65 Proximal 
colon
A Moderate 29 C→A Ser→Tyr Present No No
a Tumours of 464 sporadic colorectal cancer patients were analysed.
b 58 Tumours were selected based on absence of hMLH1 expression, 411 tumours studied were selected based on absence of a truncating APC 
mutation.
c Two patients (numbers 6 and 7) harboured a CTNNB1 mutation that would not lead to loss of a known phosphorylation site.Page 4 of 11
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a CTNNB1 mutation, these mutations were not included
in further analyses. In addition, mutation analysis of
remaining samples was abandoned, since this was
deemed irrelevant as these harboured truncating APC
mutations and are considered to be unlikely to also have
CTNNB1 mutations [7].
Of 656 tumours for which the other molecular alterations,
i.e. mutations in the APC and K-ras genes and hMLH1
expression, were all successfully and completely analysed,
103 colorectal tumours did not harbour a truncating or
missense APC mutation, an activating K-ras mutation or
showed lack of hMLH1 expression, as depicted in figure 1.
Truncating as well as missense APC mutations and activat-
ing K-ras mutations were relatively common. Truncating
APC mutations alone and activating K-ras mutations in
codons 12 and 13 only, occurred at similar frequencies
(20% (130/656) and 18% (121/656), respectively). A
combination of a truncating mutation in APC and an acti-
vating mutation in K-ras occurred less often than the sole
occurrences of mutations in both genes. However, as
shown in table 2, the simultaneous occurrence of muta-
tions in both genes occurred more frequently than
expected on the basis of chance alone. A χ2 test for the
occurrence of a truncating APC mutation and an activat-
ing K-ras mutation revealed that the occurrence of these
mutations was not independent (χ2 = 8.7, P < 0.001), but
the correlation was weak (Cramérs V = 0.138). Finally,
although 11 tumours that harboured a mutation in the
APC or K-ras gene also lacked hMLH1 expression, hMLH1
deficiency occurred more frequently in tumours that did
not harbour these mutations (χ2 = 36.6, P < 0.001).
With respect to the localisation in the colorectal tract,
tumours of the rectosigmoid and rectum more frequently
harboured truncating APC mutations when compared to
colon tumours (P = 0.001), as shown in table 3. Rectosig-
moid and rectal tumours have a relatively higher fre-
quency of K-ras mutations in codons 12 and 13 when
compared to colon tumours (P = 0.05) (Table 3). Nine per
cent of tumours showed hMLH1 deficiency, as deter-
mined by immunohistochemistry (Figure 2). Tumours
lacking hMLH1 expression occur almost exclusively in the
proximal colon (P < 0.001) and relatively more frequently
show poor differentiation or are undifferentiated (P <
0.001) when compared to tumours with hMLH1 expres-
sion (Table 3).
Next, we compared the patient and tumour characteristics
of tumours harbouring a truncating APC and/or an acti-
vating K-ras mutation to those of tumours without
hMLH1 expression, and these results are presented in
table 4. Patients harbouring hMLH1 deficient tumours
were slightly older when diagnosed with colorectal cancer
(69.3 yr (68.0–70.5) versus 67.8 (67.4–68.3), P = 0.03),
were relatively less frequently men (40% versus 58%, P =
0.02). Tumours without hMLH1 expression occurred rel-
atively more frequently in the proximal colon (P < 0.001)
and relatively more frequently showed poor differentia-
tion or are undifferentiated (P < 0.001).
Table 2: Crosstabulation of patients with and without activating K-ras and truncating APC mutation(s).
Activating K-ras mutation Truncating APC mutation
No Yes Total
No 258 136 421
expecteda 263.8 157.2
Yes 126 109 235
expecteda 147.2 87.8
Total 411 245 656
a Expected based on chance alone. χ2 = 8.7, P < 0.001
Distribution of aberrations in the APC and K-ras genes and hMLH1 expression in 656 color ctal tumoursFigure 1
Distribution of aberrations in the APC and K-ras genes and 
hMLH1 expression in 656 colorectal tumours. The data in 
this figure are based on tumours from 656 sporadic colorec-
tal cancer patients. The bars representing the different 
molecular alterations represent mutually exclusive groups of 
tumours. The category "Other" includes; APC silent mutation 
(n = 25), K-ras mutations other than missense mutations in 
codons 12 and 13 (n = 2), and both of these (n = 1).
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BMC Cancer 2005, 5:160 http://www.biomedcentral.com/1471-2407/5/160Table 3: Comparisons between patients with or without a K-ras or APC mutation and hMLH1 expression.
Genetic aberration
APCa K-rasb hMLH1 expression
No mutation
(truncation)
Mutation
(truncation)
No mutation
(codon 12/13)
Mutation
(codon 12/13)
Present Absent
Number of patients (%) 411 (63) 245 (37) 421 (64) 235 (36) 598 (91) 58 (9)
Age at diagnosis (yr, mean (SD)) 68.2 (4.3) 67.5 (4.2) 67.7 (4.3) 68.3 (4.3) 67.9 (4.2) 68.7 (4.7)
P-value 0.07 0.08 0.18
Sex (% male) 54 58 56 55 57 45
P-value 0.45 0.84 0.08
Family history of colorectal cancer (% yes) 10 9 11 7 10 9
P-value 0.89 0.07 0.79
Tumour sub-localisationc
Proximal colon 151 (69%) 67 (31%) 141 (65%) 77 (35%) 169 (78%) 49 (12%)
Distal colon 138 (68%) 66 (32%) 144 (71%) 60 (29%) 199 (98%) 5 (2%)
Rectosigmoid 34 (47%) 39 (53%) 44 (60%) 29 (40%) 73 (100%) 0 (0%)
Rectum 83 (55%) 67 (45%) 85 (57%) 65 (43%) 146 (97%) 4 (3%)
P-value <0.001 0.05 <0.001
Dukes' stagec
A 94 (60%) 63 (40%) 103 (66%) 54 (34%) 142 (90%) 15 (10%)
B 147 (67%) 73 (33%) 142 (65%) 78 (35%) 192 (87%) 28 (13%)
C 97 (60%) 64 (40%) 107 (66%) 54 (34%) 151 (94%) 10 (6%)
D 39 (54%) 33 (46%) 40 (56%) 32 (44%) 69 (96%) 3 (4%)
P-value 0.21 0.42 0.07
Differentiationc
Good 35 (56%) 28 (44%) 40 (63%) 23 (37%) 59 (94%) 4 (6%)
Moderate 250 (62%) 156 (38%) 258 (64%) 148 (34%) 380 (94%) 26 (6%)
Poor 66 (69%) 30 (31%) 68 (71%) 28 (29%) 82 (85%) 14 (15%)
Undifferentiated 6 (86%) 1 (14%) 5 (71%) 2 (29%) 4 (57%) 3 (43%)
P-value 0.20 0.57 <0.001
a APC mutations: only mutations resulting in a stop codon.
b K-ras mutations: only activating mutations in codon 12 or 13.
c Tumour sublocalisation, Dukes's stage and differentiation gave rise to missing values.
When comparing tumours with a missense (but not a
truncating) mutation in APC to tumours with a truncating
mutation in APC, missense mutations occurred relatively
more frequently in the colon (P = 0.002), less often also
harboured an activating K-ras mutation (P = 0.004), and
more often also lacked hMLH1 expression (P < 0.001). No
differences were observed with regard to age at diagnosis,
gender, Dukes' stage or tumour differentiation (data not
shown).
Finally, to assess agreement between hMLH1 expression
and microsatellite instability, both hMLH1 expression
and BAT-26 were analysed in 162 tumours. All tumours
that had normal BAT-26, also showed hMLH1 expression.
Fourteen tumours with unstable BAT-26 also lacked
hMLH1 expression, and two tumours with unstable BAT-
26 were found to express hMLH1, which demonstrates a
high agreement between these molecular features of mis-
match repair deficiency.
Discussion
In this study, the occurrence of mutations in the APC,
CTNNB1 and K-ras genes as well as expression of the
hMLH1 protein in tumour tissue of 656 sporadic colorec-
tal cancer cases were investigated. The occurrence of muta-
tions in the CTNNB1 gene, which codes for β-catenin, was
rare: only five of 464 tumours analysed were found to
have a mutation at one of the phosphorylation sites in
exon 3. Truncating mutations in APC and activating muta-
tions in K-ras appeared to occur at similar frequencies.
Although tumours harbouring both mutations were rela-
tively rare, mutations in APC and K-ras seemed to occur
co-dependently. Nine percent of all tumours (58/656)
lacked hMLH1 expression, and in these tumours almost
no APC or K-ras mutations was detected. Patients har-
bouring a tumour with absent hMLH1 expression were
older, more often women, more often had proximal colon
tumours that showed poorer differentiation when com-
pared to patients who harboured a tumour with an APC
and/or K-ras mutation.Page 6 of 11
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on the completeness of analyses of both APC and K-ras
genes as well as hMLH1 expression and this led to a con-
siderable reduction in the number of cases that could be
included in the analyses presented in this study. The larg-
est reduction (72 cases) was due to incompleteness of the
analysis of all fragments comprising the APC mutation
cluster region. Tumour DNA was derived from formalin-
fixed, paraffin-embedded tumour tissue blocks. Depend-
ing on the conditions of fixation and storage, the extracted
DNA is more or less fragmented, which may have
impaired the analysis of mutations in the APC gene more
than in the K-ras gene, since the analysis of the latter is
based on the amplification of a smaller gene fragment. It
should be emphasized that characteristics of patients (age,
sex, family history of colorectal cancer) and tumours (sub-
localisation, Dukes' stage and differentiation) of the
group under study are similar to the 737 patients for
whom tumour material was available and to all 819
patients initially recognized within the cohort (data not
shown). Moreover, the K-ras and hMLH1data presented
here are similar to the data for K-ras and hMLH1 based on
the complete groups (737 and 724 cases, respectively)
(data not shown).
Mutations in exon 3 of the CTNNB1 gene leading to loss
of one of the phosphorylation sites were rare. Strikingly,
all five of these mutations occurred in the proximal colon
and three of these also had absent hMLH1 expression.
This may indicate that these proximal colon tumours,
which often also show mismatch repair deficiency, are
more likely to harbour CTNNB1 mutations. This was also
found in a study of microsatellite instable colorectal
tumours [26]. The WAVE screening technique has not
been used previously for formalin-fixed, paraffin-embed-
ded tissue, and therefore it seems plausible that samples
harbouring a CTNNB1 mutation have escaped detection.
However, all 58 hMLH1 deficient samples were analysed
by direct sequencing without a prior screening step, and
only three of these samples harboured a CTNNB1 muta-
tion, indicating the low frequency of such mutations.
The model describing the accumulation of genetic altera-
tions of the APC, K-ras, TP53 and SMAD4 genes that drive
the development of a carcinoma, has become generally
accepted as a paradigm for the genetic basis of colorectal
carcinogenesis [3,32]. The relatively low frequency of
simultaneous occurrence of mutations in both APC and
K-ras observed in this study seems to argue against this
synergy. This contention is in accordance with observa-
tions from another cohort study, in which APC, K-ras and
TP53 gene mutations were studied in 109 tumours and
these mutations were found to rarely occur together in the
same tumour [9]. However, the simultaneous occurrence
of APC and K-ras mutations observed in our study occurs
more frequently than expected based on chance alone and
therefore mutations in the APC and K-ras genes do not
seem to occur independently. When data on APC and K-
ras mutations are derived from the study by Smith et al.
Table 4: Comparisons between patients with an APC and/or K-ras mutation and absent hMLH1 expression.
APCb and/or K-rasc mutation Absence of hMLH1 P-value
Number of patientsa 360 47
Age at diagnosis (yr, mean (SD)) 67.8 (4.2) 69.3 (4.3) 0.03
Sex (% male) 58 40 0.02
Family history of colorectal cancer (% yes) 8 11 0.60
Tumour sub-localisation <0.001
Proximal colon 96 (70%) 41 (30%)
Distal colon 107 (97%) 3 (3%)
Rectosigmoid 51 (100%) 0 (0%)
Rectum 100 (97%) 3 (3%)
Dukes' stage 0.08
A 86 (90%) 10 (10%)
B 117 (84%) 23 (16%)
C 89 (91%) 9 (9%)
D 47 (94%) 3 (6%)
Differentiation <0.001
Good 37 (92%) 3 (8%)
Moderate 232 (92%) 20 (8%)
Poor 43 (78%) 12 (22%)
Undifferentiated 1 (33%) 2 (67%)
a Patients with both absent hMLH1 expression and an APC or K-ras mutation were excluded from the analysis.
b APC mutations: only mutations resulting in a stop codon.
c K-ras mutations: only activating mutations in codon 12 or 13.Page 7 of 11
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could be obtained.
The K-ras mutation frequency of 37% is in accordance
with reported frequencies of 30 to 60% [33-43]. The fre-
quency of 37% of truncating mutations in the mutation
cluster region of APC in this study, however, seems low in
comparison to the general assumption that most colorec-
tal tumours harbour a mutation in the APC gene. When
only reports from studies on sporadic rather than familial
colorectal cancer or colorectal cancer cell lines are consid-
ered, the mutation frequencies are lower and vary
between 30 and 70% [17,44-49], and a population-based
case-control study in the Netherlands reported a 32%
mutation frequency [50].
The method for mutation analysis of the APC mutation
cluster region and exon 1 of K-ras is based on nested
amplification and direct sequencing of purified PCR frag-
ments, a highly sensitive method. Since no screening step
was performed prior to the sequencing of the gene frag-
ments, it is unlikely that mutations would have escaped
detection. The reproducibility of the applied assays was
good, with a reproducibility of 85% and 88% for APC and
K-ras, respectively. Arguably, this indicates the extent of
heterogeneity present in the tumour samples.
In 103 sporadic colorectal cancers no alterations were
found in the K-ras, APC or hMLH1 genes. It is plausible
that these tumours have harboured mutations in other
components of the Wnt signalling pathway, e.g. muta-
tions in the Axin genes, which are essential for the degra-
dation of β-catenin, and were observed in 11% of patient
samples [51]. In addition, an epi-genetic change, i.e. pro-
motor hypermethylation of the APC gene that leads to
impaired APC function has been observed in 18% of spo-
radic colorectal adenomas and carcinomas [52].
Of the microsatellite instable tumours, approximately
90% show absence of hMLH1 expression [24]. In most
sporadic colorectal cancers, the promoter region of
hMLH1 is hypermethylated, resulting in absence of the
protein [53-55]. BAT-26 was previously shown to identify
microsatellite instability in sporadic colorectal cancer [56]
and results from our study showed a good agreement
between unstable BAT-26 and absent hMLH1 expression.
Several studies have shown that microsatellite instability
and mutations in APC and K-ras occur almost mutually
exclusively [18,19,21,57], suggesting that these character-
istics represent separate pathways. However, others have
observed aberrations in both pathways, but these studies
have been performed in relatively small groups of HNPCC
and sporadic colorectal cancer patients [14,20,58] and
this may have given rise to a relative overrepresentation of
mutation detection in both pathways. Although in our
study the simultaneous occurrence of hMLH1 deficiency
as well as an APC or K-ras mutation was observed in a
small number of tumours, the mutually exclusive occur-
rence of hMLH1 deficiency and mutations in APC and/or
K-ras seemed to predominate.
Moreover, after exclusion of tumours displaying this over-
lap, a striking difference between occurrences of APC and/
or K-ras mutations versus absence of hMLH1 expression
was observed. The differences were most pronounced
with regard to tumour sub-localisation and differentia-
tion. hMLH1 deficient tumours occur almost exclusively
in the proximal colon and are relatively more frequently
poorly differentiated, which is in accordance with reports
from other studies [22-25].
hMLH1 immunohistochemistryFigure 2
hMLH1 immunohistochemistry. Present (top panel) and 
absent (bottom panel) immunohistochemical staining for 
hMLH1.Page 8 of 11
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In conclusion, this study shows that mutations in the
CTNNB1 gene are presumably of minor importance in
sporadic colorectal cancer. Although APC and K-ras muta-
tions are often observed seperately in a tumour, these
mutations seem to also occur in a co-dependent manner.
Tumours that display mismatch repair deficiency, may
form a distinct sub-group as they differ from tumours with
APC and/or K-ras mutations with regard to age, sex,
tumour sub-localisation and differentiation.
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